Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Insitu Biologics Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, resulting in a one-to-one ratio of examiners to pending matters. The prosecution involves 2 distinct art units, indicating that the applications are grouped into two separate technical divisions at the USPTO.
The busiest examiner for this portfolio is CORNET, JEAN P, who handles 1 pending office action. Because each of the 3 distinct examiners is responsible for exactly 1 pending action, the company's prosecution is entirely decentralized at the individual level. This distribution means that the company must navigate three different sets of examiner preferences across the 3 pending office actions.
With 2 distinct art units overseeing the 3 pending actions, there is some administrative consolidation despite the variety of examiners. Practitioners should look for consistency in how these 2 art units handle Biotechnology & Pharmaceuticals cases. The decentralized nature of the 3 distinct examiners suggests that the company is receiving a broad spectrum of feedback from the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615846 | SUSTAINED RELEASE CANCER THERAPEUTICS FORMULATIONS | OLSON, ANDREA STEFFEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17965738 | ECHOGENIC COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PAIN | HOERNER, PAUL ELLSWORTH | 240d overdue |
| 18631935 | SUSTAINED RELEASE STABLE EMULSION PHARMACEUTICAL FORMULATIONS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18631935 | SUSTAINED RELEASE STABLE EMULSION PHARMACEUTICAL FORMULATIONS | CORNET, JEAN P | 1628 | §103§112DP | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18615846 | SUSTAINED RELEASE CANCER THERAPEUTICS FORMULATIONS | OLSON, ANDREA STEFFEL | — | §102§103 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 17965738 | ECHOGENIC COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PAIN | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | 240d overdue | Pending | Oct 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial